The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Overcoming the challenges in prolonging remission in AML
Firas El Chaer, MD, University of Virginia, Charlottesville, VA, discusses challenges in prolonging remission in acute myeloid leukemia (AML). He highlights two main areas where efforts can be focused: eradicating measurable residual disease (MRD) prior to stem cell transplantation (SCT) or incorporating post-stem-cell maintenance. New targeted therapies could be used in both of these areas as they tend to have fewer side effects than traditional treatments such as chemotherapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
